Molecular therapeutics in breast cancer
6 – 10 of 24
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer
(
- Contribution to journal › Article
- 2021
-
Mark
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
(
- Contribution to journal › Article
-
Mark
Molecular analyses of triple-negative breast cancer in the young and elderly
(
- Contribution to journal › Article
-
Mark
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
(
- Contribution to journal › Article
-
Mark
MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer
(
- Contribution to journal › Article